20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
The FDA has placed a partial clinical hold on Yumanity Therapeutics Inc's (NASDAQ:YMTX) multidose clinical trials of YTX-7739, currently being developed for Parkinson's disease.
- The FDA has not halted all clinical programming and permits the Company's planned single-dose clinical trial to proceed.
- The partial clinical hold suspends the initiation of multiple-dose clinical trials in the U.S. until the FDA's questions have been addressed.
- Related: Yumanity Therapeutics Stock Plunges After Parkinson's Trial Data.
- The Company expects to receive additional detail from the FDA within the next 30 days.
- Related content: Benzinga's Full FDA Calendar.
- YTX-7739 is Yumanity Therapeutics' proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase.
- Price Action: YMTX shares are down 20.4% at $1.95 during the market session on the last check Wednesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!